Snapshot from Jul 19, 2026 at 11:46 UTC. For live data and tracking: View Live
Events / Regulatory / Grail securities fraud class action
Regulatory securities fraud lawsuit

Grail securities fraud class action

Analysis based on 7 articles · First reported Jul 08, 2026 · Last updated Jul 14, 2026

Sentiment
-30
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Grail's stock price dropped 50.5% on the trial failure news, erasing significant market value. The securities fraud lawsuits may lead to additional financial liabilities and reputational damage for the company.

biotechnology healthcare
Event Summary

Multiple law firms (Glancy Prongay & Murray, Law Offices of Howard G. Smith, The Law Offices of Frank R. Cruz) have filed securities fraud class action lawsuits against Grail, Inc. (Nasdaq: GRAL) on behalf of investors who purchased Grail common stock between May 13, 2025 and February 19, 2026. The lawsuits allege that Grail and its executives made materially false and misleading statements regarding the NHS-Galleri trial, failing to disclose that confidence in positive top-line results was misplaced and that longer follow-up time would be needed to demonstrate the primary endpoint. On February 19, 2026, Grail announced that the primary endpoint of statistically significant Stage III-IV cancer reduction was not observed, causing its stock price to fall 50.5% to $50.21 per share. The lead plaintiff deadline is August 4, 2026.

Key Actions
100 Illumina — Holy Grail announced trial endpoint not observed
100 Illumina — Holy Grail stock price fell
80 Glancy Prongay & Murray filed lawsuit Illumina — Holy Grail
80 The Law Offices of Frank R. Cruz filed class action lawsuit Illumina — Holy Grail
Entities Involved
subs
Illumina — Holy Grail
Grail is the defendant in securities fraud class actions following a failed cancer trial that caused a 50.5% stock drop. The company faces legal and financial repercussions.
Importance 100.0 Sentiment -80.0
priv
Glancy Prongay & Murray
The law firm is one of the lead plaintiffs' counsel in the securities fraud class action against Grail.
Importance 30.0 Sentiment 10.0
priv
The Law Offices of Frank R. Cruz
The law firm is representing investors in the securities fraud class action against Grail.
Importance 20.0 Sentiment 10.0
exch
Nasdaq
Nasdaq is the exchange where Grail's stock is listed; the event does not directly affect Nasdaq.
Importance 10.0 Sentiment 0.0
per
Howard G. Smith
Howard G. Smith is an attorney at Law Offices of Howard G. Smith involved in the Grail lawsuit.
Importance 10.0 Sentiment 5.0
per
Charles Linehan
Charles Linehan is an attorney at Glancy Prongay & Murray involved in the Grail lawsuit.
Importance 10.0 Sentiment 5.0
Relationships
Glancy Prongay & Murray competitor ↔ The Law Offices of Frank R. Cruz Glancy Prongay & Murray is a prominent plaintiff-side securities litigation firm that frequently co-counsels and compete
Glancy Prongay & Murray related ↔ Howard G. Smith
Glancy Prongay & Murray related ↔ Charles Linehan
The Law Offices of Frank R. Cruz related ↔ Howard G. Smith
The Law Offices of Frank R. Cruz related ↔ Charles Linehan
Howard G. Smith co-counsel ↔ Charles Linehan Howard G. Smith regularly partners with Charles Linehan to jointly file and prosecute securities class action complaints
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.